Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can adding a second diabetes drug do more than lower blood sugar?

NCT ID NCT06268977

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are testing whether adding an SGLT2 inhibitor to the usual treatment for type 2 diabetes improves blood sugar control and other metabolic measures. The trial enrolls about 482 adults with type 2 diabetes who are not already taking these drugs. Participants will be compared on changes in HbA1c, liver fat measured by FibroScan, waist circumference, blood pressure, cholesterol, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SGLT2 inhibitor drugs, a class of prescription medicines that lower blood sugar in adults with type 2 diabetes
What this could lead to
If adding these drugs helps, it could give doctors a clearer picture of how to combine diabetes medicines to improve blood sugar and liver fat at the same time.
What could go wrong
This is a Phase 4 trial testing a drug combination that is already approved, so it is unlikely to produce a surprise cure. The main risks are side effects like urinary tract infections and dehydration, which researchers will track.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

482 people

The number who actually took part.

Started

Apr 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults (≥18 years) 2. both genders ( male and female) 3. type 2 diabetic patients Exclusion Criteria: 1. history of severe hypoglycemia 2. patients with history of weight loss 3. Patients with history of recurrent UTI 4. patients already receiving SGLT2i as part of their treatment 5. very high blood glucose (A1c more than 11%) or presenting at the clinic with BG above 300 mg/dL. 6. clinical evidence of dehydration. 7. Frailty.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Assiut University Hospital

    Asyut, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.